Hypertrophic Cardiomyopathy Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Outcomes of patients with hypertrophic cardiomyopathy undergoing percutaneous left atrial appendage occlusion
(Source: Journal of Interventional Cardiac Electrophysiology)
Source: Journal of Interventional Cardiac Electrophysiology - February 27, 2024 Category: Cardiology Source Type: research

Obstruction in Hypertrophic Cardiomyopathy: Many Faces
(Source: Journal of the American Society of Echocardiography)
Source: Journal of the American Society of Echocardiography - February 27, 2024 Category: Cardiology Authors: Muhannad A. Abbasi, Kevin C. Ong, D. Brian Newman, Joseph A. Dearani, Hartzell V. Schaff, Jeffrey B. Geske Tags: Review Articles Source Type: research

Myocardial bridging in obstructive hypertrophic cardiomyopathy: a risk factor for myocardial fibrosis
This study was designed to evaluate the relations... (Source: BMC Medicine)
Source: BMC Medicine - February 27, 2024 Category: Internal Medicine Authors: Changpeng Song, Shengwei Wang, Xinli Guo, Manyun Huang, Xinxin Zheng, Jie Lu, Keshan Ji, Shihua Zhao, Jingang Cui, Shuiyun Wang and Xiaohong Huang Tags: Research article Source Type: research

Withdrawal Of Atrioventricular Nodal Blocking Agents in Patients Receiving Mavacamten: A Retrospective Single-Center Experience in A Predominantly Asian-American Cohort
Hypertrophic obstructive cardiomyopathy (HOCM) is a hereditary condition in which cardiac muscle progressively hypertrophies, leading to hypercontractility, impaired relaxation, and blockage of the left ventricular outflow tract (LVOT).1 Mavacamten is a recently approved medication that inhibits myosin activation, improving quality of life, functional status, and cardiac function.2 –6 (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - February 27, 2024 Category: Cardiology Authors: Kevin Benavente, Jesus Pino Moreno, Dipanjan Banerjee Tags: Brief Report Source Type: research

Evolving indications for transcatheter mitral edge-to-edge repair
EuroIntervention. 2024 Feb 19;20(4):e230-e238. doi: 10.4244/EIJ-D-23-00700.ABSTRACTTranscatheter mitral edge-to-edge repair (TEER) is an established procedure for managing mitral regurgitation (MR) in high-risk patients. It is effective in treating both primary and secondary MR, as reported in the surgical and interventional literature. Over time, TEER has gained popularity and achieved procedural success in various anatomies. The less invasive nature of TEER, along with its high safety profile and immediate haemodynamic improvement suggest potential benefits in high-risk populations who are not normally included in major ...
Source: EuroIntervention - February 23, 2024 Category: Cardiovascular & Thoracic Surgery Authors: Mony Shuvy Francesco Maisano Source Type: research

Corrigendum to "SUMO2-mediated SUMOylation of SH3GLB1 promotes ionizing radiation-induced hypertrophic cardiomyopathy through mitophagy activation"[Eur. J. Pharmacol. 924 (2022) 174980]
Eur J Pharmacol. 2024 Feb 22:176456. doi: 10.1016/j.ejphar.2024.176456. Online ahead of print.NO ABSTRACTPMID:38395694 | DOI:10.1016/j.ejphar.2024.176456 (Source: European Journal of Pharmacology)
Source: European Journal of Pharmacology - February 23, 2024 Category: Drugs & Pharmacology Authors: Anbo Gao Jin Zou Zhenjiang Mao Hong Zhou Gaofeng Zeng Source Type: research